GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
|
Synonyms: AK-109 | AK109
Compound class:
Antibody
Comment: Pulocimab (AK109) is a humanized IgG1 anti-KDR (VEGFR2) monoclonal antibody. It blocks binding of VEGF to KDR, and exhibits dose-dependent antitumour activity in vitro. This mechanism disrupts the neoangiogenesis that is crucial for tumour survival, thus provoking cancer cell death. Peptide sequences that compose the variable (V) domains of the heavy and light chains of pulocimab are claimed in patent WO2003075840A2 (Imclone Systems Inc.) [2].
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
| References |
|
1. Zheng Y, Zhong H, Zhao F, Zhou H, Mao C, Lv W, Yuan M, Qian J, Jiang H, Wang Z et al.. (2023)
First-in-human, phase I study of AK109, an anti-VEGFR2 antibody in patients with advanced or metastatic solid tumors. ESMO Open, 8 (2): 101156. [PMID:36989884] |
|
2. Zhu Z. (2003)
Human antibodies specific to kdr and uses thereof. Patent number: WO2003075840A2. Assignee: Imclone Systems Incorporated. Priority date: 04/03/2003. Publication date: 18/09/2003. |
